Obesity as a Risk Factor for Hepatocellular Carcinoma in a Noncirrhotic Patient

REFERENCES

• 1 Ratziu V, Bonyhay L, Di Martino V et al.. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.  Hepatology. 2002;  35 1485-1493
• 2 Cavaghan M K, Ehrmann D A, Polonsky K S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.  J Clin Invest. 2000;  106 329-333
• 3 Reaven G M. Pathophysiology of insulin resistance in human disease.  Physiol Rev. 1995;  75 473-486
• 4 Bugianesi E, Leone N, Vanni E et al.. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.  Gastroenterology. 2002;  123 139-140
• 5 Nair S, Mason A, Eason J, Loss G, Perrillo R P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?.  Hepatology. 2002;  36 150-155
• 6 Bralet M P, Regimbeau J M, Pineau P et al.. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases.  Hepatology. 2000;  32 200-204
• 7 Bioulac-Sage P, Le Bail B L, Winnock M et al.. Occurrence of hepatocellular carcinoma in nonfibrotic livers.  Hepatology. 2000;  32 1411-1412
• 8 Shimada M, Hashimoto E, Taniai M et al.. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.  J Hepatol. 2002;  37 154-160
• 9 Cotrim H P, Parana R, Braga E, Lyra R. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?.  Am J Gastroenterol. 2000;  95 3018-3019
• 10 Zen Y, Katayanagi K, Tsuneyama K et al.. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis.  Pathol Int. 2001;  51 127-131
• 11 Regimbeau J M, Colombat M, Mognol P et al.. Obesity and diabetes as a risk factor for hepatocellular carcinoma.  Liver Transpl. 2004;  10(suppl) s69-73
• 12 Brunt E M. Nonalcoholic steatohepatitis.  Semin Liver Dis. 2004;  24 3-20
• 13 Yang S, Lin H Z, Hwang J, Chacko V P, Diehl A M. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?.  Cancer Res. 2001;  61 5016-5023
• 14 Nemoto Y, Toda K, Ono M et al.. Altered expression of fatty acid metabolizing enzymes in aromatase-deficient mice.  J Clin Invest. 2000;  105 1819-1825
• 15 Reue K, Xu P, Wang X P, Slavin B G. Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene.  J Lipid Res. 2000;  41 1067-1076
• 16 Yokogawa K, Yonekawa M, Tamai I et al.. Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice.  Hepatology. 1999;  30 997-1001
• 17 Soga M, Kishimoto Y, Kawamura Y et al.. Spontaneous development of hepatocellular carcinomas in FLS mice with hereditary fatty liver.  Cancer Lett. 2003;  196 43-48
• 18 Fan C Y, Pan J, Usuda N, Yeldandi A V, Rao M S, Reddy J K. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism.  J Biol Chem. 1998;  273 15639-15645